Response from FDA is completely unclear. Have zero value for investors and unfortunately we have to wait for the full protocol and Company's decision to use or not to use vision loss as an end point. On a good side, there are no negative surprises.
Ann: Initial FDA and EMA Advice on Presendin Development, page-4
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.712M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60000 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.0¢ | 126146 | 1 |
View Market Depth
| Last trade - 16.12pm 14/05/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable